about
Advances in the management of osteosarcomaDistinct activity of the bone-targeted gallium compound KP46 against osteosarcoma cells - synergism with autophagy inhibition.Inhibiting DNA-PKCS radiosensitizes human osteosarcoma cells.The tumor suppressor miR-124 inhibits cell proliferation and invasion by targeting B7-H3 in osteosarcoma.Novel insights and therapeutic interventions for pediatric osteosarcoma.Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease.Assessment of GSK1904529A as a promising anti-osteosarcoma agent.Anti-proliferative, pro-apoptotic and anti-invasive effect of EC/EV system in human osteosarcoma.Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics.LncRNA FENDRR sensitizes doxorubicin-resistance of osteosarcoma cells through down-regulating ABCB1 and ABCC1.miR-216a inhibits osteosarcoma cell proliferation, invasion and metastasis by targeting CDK14.miRNA profiling identifies deregulated miRNAs associated with osteosarcoma development and time to metastasis in two large cohorts.SphK2 over-expression promotes osteosarcoma cell growth.Development of Chemotherapy with Cell-Cycle Inhibitors for Adult and Pediatric Cancer Therapy.Current and future therapeutic approaches for osteosarcoma.CD44 drives aggressiveness and chemoresistance of a metastatic human osteosarcoma xenograft model.[Postoperative and posttherapeutic changes after primary bone tumors : What's important for radiologists?]Predictive value of dynamic change of haemoglobin levels during therapy on treatment outcomes in patients with Enneking stage IIB extremity osteosarcoma.Peroxiredoxin-1 promotes cell proliferation and metastasis through enhancing Akt/mTOR in human osteosarcoma cells.ATF4 regulated by MYC has an important function in anoikis resistance in human osteosarcoma cells.Ginsenoside Rg3 Suppresses Proliferation and Induces Apoptosis in Human Osteosarcoma.Overexpression of SENP1 reduces the stemness capacity of osteosarcoma stem cells and increases their sensitivity to HSVtk/GCVAn analysis of the expression and function of myeloid differentiation factor 88 in human osteosarcoma
P2860
Q28067644-D3AA1736-435B-4BD5-AD91-9EC89E069D59Q38707939-9A3B4787-6CB8-4340-B016-712817E41439Q38712083-C6B6D1AA-93F2-4C57-8C55-D54B00A2AB91Q38745141-2F568329-42F5-4A4F-A193-CD6DD008613CQ38819276-01390F10-1001-4168-B0FE-C56AC063D071Q39229404-1103A8FA-4C3C-45EE-907E-105FFC9D49B5Q41472644-19C45CEB-EE55-45D5-8E3C-24EFBFC09843Q41551906-F51D1E08-8874-4F4D-92FC-0BE68AFDA4E2Q42634367-CB7CEDD0-3BEA-4AE5-8115-A647D6732FB2Q42654010-AB3D2303-4AD6-4A2F-9C1C-7F683DF838C4Q47121115-DBCDD9EF-06C1-43E2-8700-22704F492C4EQ47129949-410A991A-886E-4872-9827-C5C024A1A058Q47140549-078E78BC-4E32-4093-8356-7C8A40DB9E95Q47223079-7027CB89-5C06-4767-A942-F6DC914B4B95Q47360357-BF626532-431C-45D4-9015-E28498139C04Q48511799-780B36EF-5A5F-4D03-9A14-D89BCEF2C21CQ49546357-E61C0612-38A6-4811-89D1-E3982FC9A017Q52585085-614FA6E5-A4A1-45A6-AC87-2E60E227D107Q52680492-EEAF3AD0-9ADD-49BF-9E96-3598E8BBBAAEQ53714815-59FB1067-C19E-4884-8588-394FB5311C9AQ54957911-7048F333-5254-4221-8451-8A627C22D4D2Q58709655-55F24056-8B9C-47D1-9B73-24BA53F00CECQ58784160-F32A1D3B-A057-4E5A-8616-90D3D4E79E6C
P2860
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Future directions in the treatment of osteosarcoma.
@ast
Future directions in the treatment of osteosarcoma.
@en
type
label
Future directions in the treatment of osteosarcoma.
@ast
Future directions in the treatment of osteosarcoma.
@en
prefLabel
Future directions in the treatment of osteosarcoma.
@ast
Future directions in the treatment of osteosarcoma.
@en
P2860
P1476
Future directions in the treatment of osteosarcoma
@en
P2093
Katherine A Janeway
Michael W Bishop
P2860
P356
10.1097/MOP.0000000000000298
P577
2016-02-01T00:00:00Z